Hemogenyx Pharma Stock Price, News & Analysis

Hemogenyx Pharmaceuticals has successfully repaid convertible loans totaling $2,110,761 to Orgenesis, Inc., a step originally announced in October 2018. Both subsidiaries, Hemogenyx-Cell and Immugenyx, fulfilled the loan repayment terms. The company is poised for continued progress in developing its product candidates, backed by a substantial cash reserve that supports ongoing product development.

Hemogenyx Pharmaceuticals has secured a lease for a new 10,000 sq. ft. laboratory in New York's Mink Building, aimed at advancing its HEMO-CAR-T cell therapy for acute myeloid leukemia. The facility will feature two clean rooms designed for in-house cell manufacturing. CEO Dr. Vladislav Sandler expressed enthusiasm for the strategic location, citing collaboration opportunities with nearby Columbia University and City College. The move supports the company's anticipated growth and operational flexibility over the coming three years.

Hemogenyx Pharmaceuticals has signed a licence agreement with Eli Lilly, granting it exclusive rights to develop a CDX bispecific antibody for treating acute myeloid leukemia and other blood cancers. The agreement includes an upfront payment of US$250,000 and potential milestone payments up to US$1 million through clinical trials. This collaboration marks a significant advancement for Hemogenyx as it initiates IND-enabling studies, confirming the wider applicability of CDX beyond initial expectations. Successful therapy development could greatly impact patient survival rates for AML.

Hemogenyx Pharmaceuticals has announced its interim results for the six-month period ending June 30, 2021. Highlights include the completion of CDX antibody development with a global pharmaceutical partner and an agreement with the University of Pennsylvania for HEMO-CAR-T clinical trials. The company received two US patents for antibody technologies and made progress on its CBR/COVID-19 project. Additionally, Hemogenyx raised £12 million in development capital through convertible debt, later replaced by equity capital. The company remains focused on advancing its product candidates towards clinical trials.

Hemogenyx Pharmaceuticals has received a patent approval for monoclonal antibodies targeting the human FLT3/FLK2 receptor, significant for treating acute myeloid leukemia (AML). The patent, issued on August 31, 2021, adds to the company's intellectual property portfolio, which includes the CDX antibody and HEMO-CAR-T therapies. This development is crucial as it underpins ongoing collaboration with a leading pharmaceutical partner and aims to progress to clinical trials. Hemogenyx's advancements in AML therapies could affect survival rates, as current treatments yield low five-year survival rates.

Dr. Alan E. Walts has joined Hemogenyx Pharmaceuticals as a Board observer and business advisor, bringing over 25 years of biopharmaceutical experience. His background includes significant roles at Genzyme and various biotechnology firms. Dr. Walts' expertise is expected to accelerate Hemogenyx's development pipeline, particularly in new therapies for blood diseases. CEO Dr. Vladislav Sandler expressed optimism about Dr. Walts' addition, noting its potential to enhance the company’s strategic direction and R&D efforts.

Hemogenyx Pharmaceuticals has released a new corporate presentation detailing its work in developing innovative therapies for deadly blood diseases. The company, based in London with operations in New York City, focuses on advancing treatments for conditions like leukemia, lymphoma, and severe autoimmune diseases. With over 50 years of experience in bone marrow transplantation, Hemogenyx aims to improve patient outcomes and broaden access to these life-saving procedures. The presentation can be accessed here.

Hemogenyx Pharmaceuticals (OTC PINK:HOPHF) announced the successful passing of all resolutions at its Annual General Meeting (AGM) held on June 25, 2021. Key resolutions included the approval of the 2020 Annual Report and Accounts with 99.87% votes in favor, and the Directors' Remuneration Policy which received 99.07% approval. The total votes cast amounted to 126,796,363, representing 12.94% of the issued share capital. The AGM's outcomes reflect strong shareholder support for the management's proposals.

Hemogenyx Pharmaceuticals has announced that its Annual General Meeting (AGM) on June 25, 2021, will be a closed meeting due to COVID-19 restrictions in the UK. Only two specified Shareholders will attend to ensure quorum. Other Shareholders are encouraged to vote by proxy, appointing 'the Chair of the AGM.' While remote access will be provided for Shareholders to observe, they cannot vote electronically. The voting will occur via a poll to acknowledge proxy votes, with results published shortly after the AGM.